1 Toots M, Yoon JJ, Cox RM, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med 2019; 11(515).
2 Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740–6.
3 Malone B, Campbell EA. Molnupiravir: coding for catastrophe. Nat Struct Mol Biol. 2021;28(9):706–8.
4 Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Remdesivir against COVID-19 and Other Viral Diseases. Clin Microbiol Rev. 2020;34(1).
5 V’Kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155–70.
6 Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung SH. An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. J Med Chem. 2016;59(14):6595–628.
7 Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586–93.
8 Urakova N, Kuznetsova V, Crossman DK, et al. β-d-N (4)-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome. J Virol. 2018;92(3).
9 Reynard O, Nguyen XN, Alazard-Dany N, Barateau V, Cimarelli A, Volchkov VE. Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication. Viruses. 2015;7(12):6233–40.
10 Agostini ML, Pruijssers AJ, Chappell JD, et al. Small-Molecule Antiviral β-d-N (4)-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance. J Virol. 2019;93(24).
11 Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12(541).
12 Wahl A, Gralinski LE, Johnson CE, et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021;591(7850):451–7.
13 Painter WP, Holman W, Bush JA, et al. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2. Antimicrob Agents Chemother. 2021;65(5).
14 Khoo SH, Fitzgerald R, Fletcher T, et al. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. J Antimicrob Chemother. 2021;76(12):3286–95.
15 Fischer WA, 2nd, Eron JJ, Jr., Holman W, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med 2022; 14(628): eabl7430.
16 Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med 2021.
17 Boras B, Jones RM, Anson BJ, et al. Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19. bioRxiv 2021: 2020.09.12.293498.
18 Hoffman RL, Kania RS, Brothers MA, et al. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. J Med Chem. 2020;63(21):12725–47.
19 Dampalla CS, Zheng J, Perera KD, et al. Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection. Proc Natl Acad Sci U S A. 2021;118(29).
20 Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. New England Journal of Medicine 2022.
21 Li P, Wang Y, Lavrijsen M, et al. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. 2022:1–3.
22 Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022:105252.
23 Merck. FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR MOLNUPIRAVIR. Available at: https://www.fda.gov/media/155054/download. Accessed January 28, 22.
24 Pfizer. FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVID. Available at: https://www.fda.gov/media/155050/download. Accessed January 28, 2022.
25 Cully M. A tale of two antiviral targets - and the COVID-19 drugs that bind them. Nat Rev Drug Discov. 2022;21(1):3–5.
26 Gilead. Press Release: FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression. Available at: https://www.gilead.com/news-and-press/press-room/press-releases/2022/1/fda-approves-veklury-remdesivir-for-the-treatment-of-nonhospitalized-patients-at-high-risk-for-covid19-disease-progression. Accessed January 28, 2022.
27 Lo MK, Shrivastava-Ranjan P, Chatterjee P, et al. Broad-Spectrum In Vitro Antiviral Activity of ODBG-P-RVn: An Orally-Available, Lipid-Modified Monophosphate Prodrug of Remdesivir Parent Nucleoside (GS-441524). Microbiol Spectr. 2021;9(3):e0153721.
28 Cox RM, Wolf JD, Lieber CM, et al. Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets. Nat Commun. 2021;12(1):6415.
29 SHIONOGI. Briefing Session on COVID-19 Therapeutic Drug S-217622, February 7, 2022, Transcription. Available at: https://www.shionogi.com/content/dam/shionogi/global/investors/ir-library/presentation/2021/e20220207_script.pdf. Accessed February 16.
30 SHIONOGI. Top-Line Results of the Phase 2a Part of the Phase 2/3 Trial of S-217622, the COVID-19 Therapeutic Drug, February 7, 2022, Presentation. Available at: https://www.shionogi.com/content/dam/shionogi/global/investors/ir-library/presentation/2021/e20220207_3.pdf. Accessed February 16.
31 Biosciences P. INFORMATION ON PBI-0451: PBI-0451, an Investigational Coronaviral Protease Inhibitor. Available at: https://www.pardesbio.com/pipeline/. Accessed January 28, 2022.
32 Jiang L-J. EDP-235, A Potential Oral, Once-Daily Antiviral Treatment and Preventative for COVID-19. International Society for Influenza and Other Respiratory Virus Diseases (ISIRV). Virtual: WHO, 2019.
33 PHARMACEUTICALS E. Press Release: ENANTA PHARMACEUTICALS PRESENTS NEW DATA FOR EDP-235, ITS LEAD ORAL PROTEASE INHIBITOR DESIGNED FOR THE TREATMENT OF COVID-19, AT THE ISIRV–WHO VIRTUAL CONFERENCE 2021. Available at: https://www.enanta.com/investors/news-releases/press-release/2021/Enanta-Pharmaceuticals-Presents-New-Data-for-EDP-235-its-Lead-Oral-Protease-Inhibitor-Designed-for-the-Treatment-of-COVID-19-at-the-ISIRVWHO-Virtual-Conference-2021/default.aspx. Accessed January 28, 2022.
5 V’Kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155–70.
15 Fischer WA 2nd, Eron JJ Jr, Holman W, Cohen MS, Fang L, Szewczyk LJ, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022;14(628):abl7430.
16 Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al.; MOVe-OUT Study Group. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med 2021;386:509–20.
20 Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al.; EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022:NEJMoa2118542.
21 Li P, Wang Y, Lavrijsen M, Lamers MM, de Vries AC, Rottier RJ, et al. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. 2022:1–3.